![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Metrics Contract Services, the contract pharmaceutical development and manufacturing division of Mayne Pharma, welcomes Stephanie Emory, PhD as Associate Director of Pharmaceutical Development.
In that capacity, Stephanie directs a team of formulation scientists who develop oral solid dose formulations for Phase I through Phase III clinical trials, and then scale up and support the validation and commercialization of those products.
Additionally, she oversees Metrics’ Pharmaceutical Development Lab – the fast track/small scale specialty lab that focuses on quick-start formulation development and analytical testing. In this capacity, she evaluates new technologies that can benefit client-sponsored programs.
Stephanie reports to Brad Gold, Vice President of Pharmaceutical Development for Metrics Contract Services, who said: “Dr. Emory is a proven leader in the CDMO space, and she comes with a strong background in product development and specifically, bioavailability enhancement of small molecule formulations. Her diverse skill sets will enhance our product development expertise as well as increase productivity by ensuring the efficient management of resources. She will be an effective and strategic leader who will help manage a broad spectrum of vital projects.”
Stephanie comes to Metrics Contract Services most recently from the FDA where she reviewed the CMC/Drug Product portions of INDs, NDAs, and industry meeting packages for CDER’s Office of Pharmaceutical Quality. Prior to FDA she spent seven years at UPM Pharmaceuticals, Inc., a then Baltimore-based CDMO, serving as both technical lead and project manager for the development of Pre-clinical through Phase III clinical supplies. She has experience with a wide range of solid oral dosage forms and manufacturing processes, including solubility-enhancing formulations, as well as scale-up, tech transfer, and process validation activities.
Emory holds a Bachelor of Science in Pharmaceutical Sciences and a doctorate in Industrial & Physical Pharmacy from Purdue University.
About Metrics Contract Services
Metrics Contract Services is a full-service pharmaceutical development and manufacturing organization serving clients worldwide delivering proven scientific and operational excellence for novel oral dosage forms. Metrics’ areas of expertise include quality pharmaceutical formulation development; first-time-in-human formulations; Phase I-III clinical trial materials manufacturing; and analytical method development and validation services leading to commercial scale manufacturing. Technical capabilities include highly potent and unstable compounds; Schedule II-V controlled substances; and products with poor bioavailability, for which we offer an impressive portfolio of advanced delivery methods. Metrics manufactured products are now approved by medicines regulators in more than 40 countries. Located in Greenville, N.C., Metrics is a proud member of Mayne Pharma.
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on the application of drug delivery expertise to commercialize branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems, and these technologies have been successfully commercialized in numerous products that continue to be marketed around the world. Mayne Pharma has two drug development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral and topical dose forms including potent compounds, modified-release products and poorly soluble compounds.
